Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
G Zhu, L Pei, H Xia, Q Tang, F Bi - Molecular cancer, 2021 - Springer
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …
Liver metastases
Liver metastases are commonly detected in a range of malignancies including colorectal
cancer (CRC), pancreatic cancer, melanoma, lung cancer and breast cancer, although CRC …
cancer (CRC), pancreatic cancer, melanoma, lung cancer and breast cancer, although CRC …
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA
Circulating tumor-derived DNA (ctDNA) is an emerging biomarker for many cancers, but the
limited sensitivity of current detection methods reduces its utility for diagnosing minimal …
limited sensitivity of current detection methods reduces its utility for diagnosing minimal …
Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics
Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …
Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …
Clinical application and detection techniques of liquid biopsy in gastric cancer
S Ma, M Zhou, Y Xu, X Gu, M Zou, G Abudushalamu… - Molecular Cancer, 2023 - Springer
Gastric cancer (GC) is one of the most common tumors worldwide and the leading cause of
tumor-related mortality. Endoscopy and serological tumor marker testing are currently the …
tumor-related mortality. Endoscopy and serological tumor marker testing are currently the …
Circulating tumor DNA and liquid biopsy in oncology
Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …
[HTML][HTML] The emerging role of cell-free DNA as a molecular marker for cancer management
AJ Bronkhorst, V Ungerer, S Holdenrieder - Biomolecular detection and …, 2019 - Elsevier
An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …
Liquid biopsies come of age: towards implementation of circulating tumour DNA
Improvements in genomic and molecular methods are expanding the range of potential
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …
applications for circulating tumour DNA (ctDNA), both in a research setting and as a'liquid …
Integrating liquid biopsies into the management of cancer
During cancer progression and treatment, multiple subclonal populations of tumour cells
compete with one another, with selective pressures leading to the emergence of …
compete with one another, with selective pressures leading to the emergence of …